Skye Bioscience, Inc.
SKYE
$2.23
$0.3518.62%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -50.49M | -57.33M | -55.92M | -51.23M | -42.37M |
| Total Depreciation and Amortization | 689.40K | 718.90K | 723.40K | 718.70K | 605.80K |
| Total Amortization of Deferred Charges | -- | -- | -- | 0.00 | 111.50K |
| Total Other Non-Cash Items | 9.70M | 6.71M | 7.41M | 8.24M | 3.79M |
| Change in Net Operating Assets | 1.29M | 7.47M | 4.73M | 805.80K | 4.50M |
| Cash from Operations | -38.81M | -42.44M | -43.06M | -41.47M | -33.37M |
| Capital Expenditure | 0.00 | 0.00 | -6.30K | -56.30K | -1.57M |
| Sale of Property, Plant, and Equipment | 450.50K | 361.70K | 360.80K | 321.20K | 302.60K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 22.75M | 3.84M | -19.85M | -16.87M | -24.75M |
| Cash from Investing | 23.20M | 4.20M | -19.50M | -16.61M | -26.02M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -178.80K | -71.50K | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | 6.44M | 6.44M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 17.70K | 29.60K | 29.60K | -6.42M | -6.42M |
| Cash from Financing | -161.10K | -41.90K | 29.60K | 23.80K | 23.80K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -15.77M | -38.27M | -62.53M | -58.05M | -59.36M |